Rice University opens biotech venture studio in TMC

rapidly scaling

In its mission to amplify and advance biotech innovation, Rice University has announced its latest initiative — a new lab focused on bringing life-saving medical technologies to commercialization.

Established to rapidly build companies based on Rice University's portfolio of over 100 patents, RBL LLC is a new biotech venture creation studio based in Texas Medical Center Helix Park. RBL comes on the heels of establishing the Rice Biotech Launch Pad, a biotech innovation accelerator that opened last year.

Paul Wotton, executive director of the Rice Biotech Launch Pad, co-founded RBL with his colleagues Omid Veiseh, Rice professor of bioengineering and faculty director of the Rice Biotech Launch Pad; Jacob Robinson, Rice professor of electrical and computer engineering; and Dr. Rima Chakrabarti, a physician scientist and venture capital investor with KdT Ventures.

“This is a pivotal moment for Houston and beyond,” Wotton, who serves as RBL’s managing partner, says in a news release from Rice. “Houston has rapidly emerged as a global life sciences powerhouse, blending cutting-edge research with early clinical applications at Rice and the city’s world-renowned hospital systems.

"Investors from across the nation are recognizing Houston’s potential, and with RBL, we’re building on that momentum," he continues. "We’ll not only amplify the work of the Rice Biotech Launch Pad but expand our reach across Texas, creating opportunities for biotech ventures statewide and driving growth for the biotech industry as a whole.”

Strategically located in TMC, RBL will collaborate with medical leaders, investors, corporations, and other players both in the same building and on the greater TMC campus.

“Leveraging Rice University’s Biotech Launch Pad breakthroughs and pairing it with the world-class translational infrastructure of TMC Helix Park well positions RBL to drive unprecedented advances in patient care,” William McKeon, president and CEO of the TMC, says in the release. “This partnership between academia, industry and health care is exactly what’s needed to transform medical discoveries into real-world solutions that improve lives globally.”

RBL is Rice's latest effort to bridge the gap between academia and biotech innovation, an effort led by Paul Cherukuri, Rice’s chief innovation officer, who reportedly spearheaded development of the new initiative.

“RBL is a game-changer for Rice, Houston and the global biotech community,” Cherukuri adds. “This venture not only accelerates the commercialization of our innovations but also sets a blueprint for other universities looking to maximize the real-world impact of their discoveries. By combining scientific expertise with entrepreneurial support from Day Zero together with strategic clinical partnerships in the TMC, we’re creating a model for driving large-scale biotech innovation that universities everywhere should aspire to replicate.”

Since the Rice Biotech Launch Pad was established, Motif Neurotech closed its series A round with an oversubscribed $18.75 million, the hub secured a $34.9 million grant, and a “living pharmacy” founded at the Launch Pad received industry validation.

“RBL provides a powerful platform to translate high-impact scientific discoveries into therapies that will dramatically improve patient outcomes,” Veiseh says. “Our goal is to rapidly bring Rice’s pioneering research into the clinic, delivering life-saving solutions to patients around the world.”

From Your Site Articles

Created through the Rice Biotech Launch Pad, Motif Neurotech is focused on developing minimally invasive bioelectronics for the treatment of psychiatric conditions. Photo via motifneuro.tech

Houston mental health tech startup receives industry validation for bioelectronic device

on the right path

A new tool in the fight against treatment-resistant depression could be on the horizon thanks to a Rice University professor.

Jacob Robinson, a professor of electrical and computer engineering and of bioengineering is also co-founder and CEO of Motif Neurotech. Created through the Rice Biotech Launch Pad, Motif Neurotech is focused on developing minimally invasive bioelectronics for the treatment of psychiatric conditions. The company closed its series A round with an oversubscribed $18.75 million earlier this year.

This week, Rice University announced that Robinson has published a peer-reviewed study in Science Advances describing his wireless device called the Digitally programmable Over-brain Therapeutic (DOT). The epidural cortical stimulator is 9 millimeters in width, meaning that it’s easily implantable but is powerful enough to send electrical stimulation to the brain through the dura, the membrane that protects the brain and spinal cord.

“It overcomes challenges by using a battery-free and wireless approach to create an implant that can deliver precise and programmable stimulation to the brain, without brain surgery,” Robinson explained in a press release.

Jacob Robinson, a professor of electrical and computer engineering and of bioengineering, is also co-founder and CEO of Motif Neurotech. Photo via motifneuro.tech

The DOT stimulator is intended to send electrical charges meant to provide neuromodulation for mental health woes including not just depression, but also obsessive compulsive disorder and post-traumatic stress disorder. The treatment could be an alternative to transcranial magnetic stimulation (TMS), a technique that has increased in popularity in recent years.

TMS uses pulsed magnetic fields to stimulate the brain. A typical TMS course includes 36 total treatments and can cause headaches. The DOT stimulator can enact the same timing patterns used in TMS, such as the intermittent theta burst stimulation (iTBS) paradigm, which has been noted to improve mood in patients, but can be achieved at home with far greater ease. Implantation takes just 20 minutes.

So far, the DOT stimulator has been implanted in both a human and a pig. In the pig, researchers noted that the electrical stimulation did not cause any damage to the brain or dura. Just as importantly, it showed stable performance for 30 days in inducing motor responses, meaning it can operate on a longer-term basis.

Motif Neurotech was founded along with Kaiyuan Yang and physicians Sunil Sheth and Sameer Sheth. The Rice Biotech Launchpad brings together local researchers like Robinson and his team with a network of industry executives. With their manuscript, entitled “Miniature battery-free epidural cortical stimulators” freshly published on the Science Advances website, big things could be coming for the bioelectronics company and for sufferers of treatment-resistant depression.

Rice team demonstrates miniature brain stimulator in humanswww.youtube.com

Motif Neurotech, which develops minimally invasive bioelectronics for mental health treatment, closed its series A round with an oversubscribed $18.75 million. Photo via Rice.edu

Rice University medical device spinout secures nearly $19M series A

fresh funding

A health tech startup based out of a newly formed accelerator program at Rice University has raised venture funding.

Motif Neurotech closed its series A round with an oversubscribed $18.75 million. The company, which develops minimally invasive bioelectronics for mental health treatment, was formed out of the Rice Biotech Launch Pad that launched last fall.

The round was led by Arboretum Ventures, with participation from new investors KdT Ventures, Satori Neuro, Dolby Family Ventures, re.Mind Capital and existing investors Divergent Capital, TMC Venture Fund, PsyMed Ventures, Empath Ventures and Capital Factory, according to a news release from Rice.

“Minimally invasive bioelectronics are the future of mental health treatment,” Jacob Robinson, CEO and founder of Motif Neurotech, says in the release. “Thirty percent of patients with depression don’t respond to two or more medications, and there is a significant need for additional treatment options that are effective and easily accessible."

The fresh funding will go toward developing the inaugural product, the DOT microstimulator, a wireless, battery-free device that can provide at-home therapy for treatment-resistant depression, or TRD, a major depressive disorder.

“This is a pivotal moment for the company as it closes its Series A in addition to the recent successful completion of the proof-of-concept first-in-human implant of the DOT stimulator device," Tom Shehab, managing partner of Arboretum Ventures, says in the release. "We believe Motif’s device will greatly improve the quality of life for patients who have been diagnosed with difficult to treat mental health disorders, including TRD."

Shehab, along with Amy Kruse, chief investment officer of Satori Neuro, will reportedly join Motif Neurotech's board of directors alongside Anthony Arnold, president and CEO of Sensydia Corporation, and Jacob Robinson, professor of electrical and computer engineering and bioengineering at Rice.

The Rice Biotech Launch Pad was established to take biotech innovations from concept to clinical trials in five years or less. It occupies 15,000 square feet of space on campus and is funded through federal grants and donations.

The first of Rice University's new moonshot initiatives, the Rice Biotech Launch Pad was announced on the 61st anniversary of President John F. Kennedy's address at Rice Stadium. Photo by Gustavo Raskosky/Rice University

New biotech lab, accelerator emerges in Houston to speed up commercialization of life-saving cures

ready to launch

A new initiative from Rice University is launching with an ambitious goal — to take biotech innovations from concept to clinical trials in five years or less.

The Rice Biotech Launch Pad is a newly announced initiative that will expedite Rice University's health and medical technology innovations. The accelerator, which will occupy 15,000 square feet of space on campus, will be funded through federal grants and donations.

“The Rice Biotech Launch Pad will ensure that our faculty and students have the skills, partnerships, tools and support to create technologies that can transform our city and the world,” Rice President Reginald DesRoches says in a press release. “More importantly, the accelerator will provide a pathway for these creations and discoveries to be turned into medical cures that significantly impact people’s lives. Rice researchers have been doing this for years. This development will allow them to do even more and at a quicker, more efficient pace.”

Leading the program are two seasoned experts: associate professor of bioengineering at Rice, Omid Veiseh, and biotech entrepreneur Paul Wotton, who co-founded Avenge Bio and other startups with technology discovered in Veiseh’s lab. Veiseh will serve as faculty director, and Wotton will lead as executive director. Veiseh says the team behind the new lab will assist faculty in their mission to garner funding — via grants from organizations such as ARPA-H, DARPA and the NIH — as well as creating pathways for licensing revenue for the university.

“We have the infrastructure, financial backing and talent in Houston to do more in creating new medicines to cure disease," Veiseh says in the release. "This is a thriving environment that warrants more attention and dedication to bring forward Houston’s medical discoveries. I am proud to help make this happen.”

The accelerator’s founding advisory council members from Rice are:

Paul Cherukuri, Rice’s vice president for innovation.
Jacob Robinson, professor of electrical and computer engineering and of bioengineering and founder and CEO of Motif Neurotech.
Ashok Veeraraghavan, professor of electrical and computer engineering and computer science and co-founder of Synopic.
Yael Hochberg, head of the Rice Entrepreneurship Initiative and the Ralph S. O'Connor Professor of Finance and Entrepreneurship at the Jesse H. Jones Graduate School of Business.

“The Biotech Launch Pad is the first in a series of Rice Moonshots that are hyper-focused on building a ‘speed and scale’ innovation ecosystem across Houston," Cherukuri says. "We at Rice are committed towards driving the Biotech Launch Pad in collaboration with our partners within the Texas Medical Center and the new Helix Park campus.”

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston's Texas Medical Center wins prestigious global award recognizing leaders in life science innovation

new bling

Last month, a global organization honored innovation leaders in life sciences, and the Texas Medical Center was among the recipients of the prestigious awards program.

The 18th annual Prix Galien Awards Gala awarded TMC Innovation with the win in the "Incubators, Accelerators and Equity" category. The Galien Foundation created the awards program in 1970 in honor of Galien, the father of medical science and modern pharmacology. Alongside TMC, the other winners represented biotech, digital health, startups, and more.

"We are super proud of this distinction," Tom Luby, director of TMC Innovation says at Envision 2024 last month, crediting the TMCi team and TMC leadership for the award. "We lean on a lot of advisers and experts — people who volunteer their time to work with startups. Without (them), we would not have been successful."

Luby explains that a Prix Galien Award holds a Nobel Prize level of significance for the community.

TMCi was named a finalist in August, and competed against programs from Cedars-Sinai, Mayo Foundation for Medical Education and Research, TechConnect, and more.

"The Awards Committee is honored to witness the exceptional dedication and creativity of our nominees as they turn visionary ideas into transformative solutions for patients worldwide," says Michael Rosenblatt, chair of the Prix Galien USA Awards Committee, in a news release. "Their unwavering commitment to advancing patient care is truly commendable, and we are honored to celebrate their outstanding contributions to global health."

The award is displayed at TMC Innovation's office, located in the medical center at 2450 Holcombe Blvd.

Houston energy transition tech SPAC goes public through IPO

BLANK CHECK

Houston-based CO2 Energy Transition Corp. — a “blank check” company initially targeting the carbon capture, utilization, and storage (CCUS) sector — closed November 22 on its IPO, selling 6 million units at $10 apiece.

“Blank check” companies are formally known as special purpose acquisition companies (SPACs). A SPAC aims to complete a merger, acquisition, share exchange, share purchase, reorganization or similar business combination in certain business sectors. CO2 Energy Transition will target companies valued at $150 million to $250 million.

Each CO2 Energy Transition unit consists of one share of common stock, one warrant to purchase one share of common stock at a per-share price of $11.50, and the right to receive one-eighth of a share of common stock based on certain business conditions being met.

The IPO also included the full exercise of the underwriter’s option to buy 900,000 units to cover over-allotments. Kingswood Capital Partners LLC was the sole underwriter.

Gross proceeds from the IPO totaled $69 million. The money will enable the company to pursue CCUS opportunities.

“Recent bipartisan support for carbon capture legislation heavily emphasized the government’s willingness to advance and support technologies for carbon capture, utilization, storage, and other purposes as efforts to reduce greenhouse gas emissions [continue],” Co2 Energy Transition says in an October 2024 filing with the U.S. Securities and Exchange Commission (SEC).

Brady Rogers is president and CEO of CO2 Energy Transition. He also is CEO of Carbon Capture Development Co., a Los Angeles-based developer of direct air capture (DAC) technology, and president of Houston-based Antelope Energy Partners LLC, a provider of oil and gas services.

------

This article originally ran on EnergyCapital.

Mastering control room management for smoother critical infrastructure operations

Up to Date

Control room management (CRM) systems play an integral role in ensuring the safe and efficient remote operations of automated processes for the world's most critical infrastructures (CI). If anything goes wrong with these CIs, the risks are major: loss of life or catastrophic environmental disasters. For this reason, rigorous regulatory requirements are crucial.

CRM systems give operators the ability to automate and take control of CI processes, giving operators situational awareness and real-time visibility of remote assets. This minimizes the need for manual work and inspection, and scales a company's ability to safely manage many assets over a large geographical area from one control room.

Most CI have to handle hazardous material in some, if not all, of their operational areas. Though different by industry, regulations and oversight are extremely necessary.

ICS (Industrial Control Systems) and CRM tools are key components of real-time monitoring for advanced warning and emergency alarming. The combination of a “green, amber, red” alert on the screen of an operator's control console will prompt them to respond, and potentially lead to following emergency shut-down response procedures. Training and testing of the control systems and their related standards, procedures, and activities are all recorded in a system of record in compliance with regulatory requirements.

Current challenges
One of the biggest challenges is the ability to easily aggregate the data from the many different systems and integrate them with the operator's daily activity and responses to the many notifications they receive. This makes it difficult for handover, when a new control room operator comes in fresh to take over from the operator coming off duty. Ensuring a clean and clear handover that encompasses all the pertinent information, so that the new operator can take over the console with ease and clarity, is much more difficult than some would imagine.

Another issue is the sheer volume of data. When you have thousands of sensors streaming data, it is not unrealistic for a console to receive a few thousand data points per second. Performance and continuity are priorities on a CI control room console(s). So there is no room for error — meaning there is no room for big (quite literally) data.

All of this means that real-time data must be pushed off the operational and process control network and moved into an area where there are no controls, but big data can be stored to produce big-data analytic capabilities, enabling AI, machine learning, and other data science.

Controller/operator fatigue is also an issue. Manual tracking, documenting, and record-keeping increases fatigue, leading to more mistakes and omissions.

Opportunities for improvement
The Houston-based Tory Technologies, Inc.is a corporation specializing in advanced software applications, creating and integrating various innovative technologies, and providing solutions for control room management and electronic flow measurement data management.

Tory Technologies, Inc. can help with the auto population of forms, inclusion of historical alarms and responses, and easy handover of control with active/open issues highlighted, making for an easier transition from one operator to the next.

"CRM is essential for keeping operations safe and efficient in industries where mistakes can lead to serious problems," says Juan Torres, director of operations - MaCRoM at Tory Technologies, Inc. "While many control rooms have worked hard to meet compliance standards, challenges remain that can affect performance and safety. It's not enough to just meet the basic rules; we need to go further by using smarter tools and strategies that make CRM more than just compliant, but truly effective."

Shaun Six, president of UTSI International, notes that, "CRM solutions are scalable. A smart integration with relevant systems and related data will reduce 'white noise' and increase relevance of data being displayed at the right time, or recalled when most helpful."

The future state
Offering CRM as a service for non-regulated control rooms will give economies of scale to critical infrastructure operators, which will allow dispatching, troubleshooting, and network monitoring so operators can focus on more value-add activities.

It can also virtualize network monitoring, ensuring that field machines and edge computers are compliant with industry and company standards and are not exposed to external threats.

Even better: Much of this can be automated. Smart tools can look through each device and test that passwords are changed, configurations are secure, and firmware/software has been properly patched or safeguarded against known exploits.

The sheer volume of data from these exercises can be overwhelming to operators. But a trained professional can easily filter and curate this data, cutting through the noise and helping asset owners address high-risk/high-probability exploits and plan/manage them.

Ultimately, the goal is to make control rooms efficient, getting the right information to the right people at the right time, while also retaining and maintaining required documents and data, ensuring an operators “license to operator” is uninterrupted and easily accessible to external parties when requested or needed.

Integrating smart CRM systems, network monitoring tools, and testing/validating processes and procedures are all easily accessible with current technological capabilities and availability, letting operators focus on the task at hand with ease and peace of mind.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME